217 related articles for article (PubMed ID: 26012644)
1. Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.
Rocca A; Farolfi A; Maltoni R; Carretta E; Melegari E; Ferrario C; Cecconetto L; Sarti S; Schirone A; Fedeli A; Andreis D; Pietri E; Ibrahim T; Montalto E; Amadori D
Breast Cancer Res Treat; 2015 Jul; 152(1):57-65. PubMed ID: 26012644
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
Bronte G; Rocca A; Ravaioli S; Puccetti M; Tumedei MM; Scarpi E; Andreis D; Maltoni R; Sarti S; Cecconetto L; Fedeli A; Pietri E; De Simone V; Asioli S; Amadori D; Bravaccini S
BMC Cancer; 2018 Mar; 18(1):348. PubMed ID: 29587674
[TBL] [Abstract][Full Text] [Related]
3. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
4. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
[TBL] [Abstract][Full Text] [Related]
5. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
[TBL] [Abstract][Full Text] [Related]
6. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
Toi M; Saji S; Masuda N; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Takada M; Ueno T; Saji S; Chanplakorn N; Suzuki T; Sasano H
Cancer Sci; 2011 Apr; 102(4):858-65. PubMed ID: 21231986
[TBL] [Abstract][Full Text] [Related]
7. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
Anderson H; Hills M; Zabaglo L; A'hern R; Leary AF; Haynes BP; Smith IE; Dowsett M
Ann Oncol; 2011 Aug; 22(8):1770-6. PubMed ID: 21285137
[TBL] [Abstract][Full Text] [Related]
8. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
10. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
Chen S; Huang L; Chen CM; Shao ZM
Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
Kuter I; Gee JM; Hegg R; Singer CF; Badwe RA; Lowe ES; Emeribe UA; Anderson E; Sapunar F; Finlay P; Nicholson RI; Bines J; Harbeck N
Breast Cancer Res Treat; 2012 May; 133(1):237-46. PubMed ID: 22286314
[TBL] [Abstract][Full Text] [Related]
12. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
13. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.
Endo Y; Toyama T; Takahashi S; Sugiura H; Yoshimoto N; Iwasa M; Kobayashi S; Fujii Y; Yamashita H
Int J Clin Oncol; 2011 Oct; 16(5):512-8. PubMed ID: 21431343
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
15. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.
Agrawal A; Robertson JF; Cheung KL; Gutteridge E; Ellis IO; Nicholson RI; Gee JM
Int J Cancer; 2016 Jan; 138(1):146-59. PubMed ID: 26178788
[TBL] [Abstract][Full Text] [Related]
16. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Delpech Y; Wu Y; Hess KR; Hsu L; Ayers M; Natowicz R; Coutant C; Rouzier R; Barranger E; Hortobagyi GN; Mauro D; Pusztai L
Breast Cancer Res Treat; 2012 Sep; 135(2):619-27. PubMed ID: 22890751
[TBL] [Abstract][Full Text] [Related]
17. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
Chang J; Powles TJ; Allred DC; Ashley SE; Makris A; Gregory RK; Osborne CK; Dowsett M
Clin Cancer Res; 2000 Feb; 6(2):616-21. PubMed ID: 10690547
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
[TBL] [Abstract][Full Text] [Related]
19. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
Penault-Llorca F; André F; Sagan C; Lacroix-Triki M; Denoux Y; Verriele V; Jacquemier J; Baranzelli MC; Bibeau F; Antoine M; Lagarde N; Martin AL; Asselain B; Roché H
J Clin Oncol; 2009 Jun; 27(17):2809-15. PubMed ID: 19380452
[TBL] [Abstract][Full Text] [Related]
20. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
